Unpacking the latest Canadian cGVHD guidelines
Episode notes
There are several international guidelines for management of chronic graft-versus-host disease (cGVHD), but what about Canadian-specific guidance on how best to manage this complex disorder?
Our podcast moderators, Dr. Gizelle Popradi, hematologist and Stem Cell Transplant Program Director at the McGill University Health Centre, and Dr. Dennis Kim, clinician at the Princess Margaret Cancer Centre, provide exclusive perspectives as authors of the latest consensus-based Canadian cGVHD guidelines.
Our experts discuss the rationale and collaborative development process behind the recently published Cell Therapy Transplant Canada (CTTC) guidelines for managing cGVHD. They explore the unique management challenges within the Canadian healthcare landscape, as well as the unmet needs these guidelines aim to address in cGVHD care across the country. Finally, our authors give their insights into the future of cGVHD treatment and how exciting developments in the field can lead to a brighter future for patients.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Gizelle Popradi:
- Direct financial relationship including receipt of honoraria: Sanofi, Servier, Mallinckrodt, AbbVie, Jazz, Medexus, Pfizer, Seattle Genetics, Takeda, Amgen, Merck, Gilead, Novartis, Kyowa Kirin, Paladin, Sobi. Funded grants, research, or clinical trials: Mallinckrodt, Syndax, AbbVie, Equillium, Amgen, Incyte.
Dr. Dennis Kim:
- Direct financial relationship including receipt of honoraria: Novartis, Sanofi, Pfizer, Jazz, Paladin. Membership on advisory board: Novartis, Sanofi, Jazz, Paladin. Funded grants, research, or clinical trials: Novartis, Sanofi, Jazz, Paladin.
MAT-CA-2401072